Navigation Links
Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
Date:6/8/2009

harmaceuticals, Inc.

Celator Pharmaceuticals, Inc., with locations in Princeton, NJ, and Vancouver, BC, is a privately held pharmaceutical company developing new and more effective therapies to treat cancer. CombiPlex(R), the company's proprietary drug ratio technology platform, represents a novel approach that identifies molar ratios of drugs that will deliver a synergistic benefit, and locks the desired ratio in a nano-scale drug delivery vehicle that maintains the ratio in patients with the goal of improving clinical outcomes. The company pipeline includes: CPX-351 (a liposomal formulation of cytarabine:daunorubicin), currently in Phase 2 in patients with acute myeloid leukemia; CPX-1 (a liposomal formulation of irinotecan:floxuridine), currently in Phase 2 in patients with colorectal cancer; CPX-571 (a liposomal formulation of irinotecan:cisplatin), a preclinical stage compound; and multiple research programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents. For more information, please visit the company's website at www.celatorpharma.com. Information about ongoing trials is available at www.clinicaltrials.gov.

List of abstracts:

  1. Feldman E, Lancet J, Kolitz JE, et al. Pharmacology of CPX-351: a nano-scale liposomal fixed molar ratio cytarabine-daunorubicin for patients with advanced leukemia. EHA Abstract #1398.
  2. Harasym T, Lim W, Tardi P, et al. Leukemia cell-selective uptake of cytarabine (Cyt) and daunorubicin (Daun) mediated by CPX-351 liposome injection in the bone marrow compartment. EHA Abstract #383


'/>"/>
SOURCE Celator Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Celator(R) Pharmaceuticals to Present at Piper Jaffray Health Care Conference and Mid-Atlantic Capital Conference
2. Celator(R) Pharmaceuticals To Present at 2008 BIO Investor Forum
3. Celator(R) Pharmaceuticals to Present at 2008 BIO International Convention
4. Celator(R) Pharmaceuticals Announces Appointment of Scott Jackson as CEO
5. Celator(R) Pharmaceuticals to Present at 10th Annual BIO CEO and Investor Conference
6. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
7. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
8. Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
9. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
10. VIA Pharmaceuticals DGAT1 Inhibitors Featured in American Diabetes Association Poster Presentation
11. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Dec. 19, 2014 Research and Markets ... of the "Technology Innovations in Smart Fabrics ... http://photos.prnewswire.com/prnh/20130307/600769 ... Fabrics" offers a detailed assessment on technological advancements ... Findings: 1. The Smart Fabrics ...
(Date:12/19/2014)... Arkansas (PRWEB) December 18, 2014 ... to locate its pilot production facility and future ... develop and produce innovative new materials that safely ... chosen not only because of its historic, strong ... leaders’ efforts to attract leading edge, technology-based companies ...
(Date:12/19/2014)... 18, 2014 Ed Bilsky, Ph.D., vice ... Center for Excellence in the Neurosciences (CEN), and professor ... been selected as a member of the prestigious Dana ... neuroscientist from Maine to receive this honor. , ... entirely by the Dana Foundation. Its mission is ...
(Date:12/19/2014)... iLab Solutions, the global leader in ... Bryant as the new Director of Institutional Implementations and ... These two new leadership positions were created to support ... that iLab continues to meet the needs of its ... iLab has been deployed at over 450 core facilities ...
Breaking Biology Technology:Technology Innovations in Smart Fabrics (Technical Insights) 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 2UNE's Ed Bilsky Named Member of Dana Alliance for Brain Initiatives 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2
... 19 Beckman Coulter,Inc. (NYSE: BEC ), ... simplify, automate, and innovate complex biomedical testing,announced today ... chief financial officer, will present at the 2007 ... 2007, at 1:00 p.m.,(EDT). (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ...
... BioCryst,Pharmaceuticals, Inc. (Nasdaq: BCRX ) today ... with intramuscular (i.m.) injection of peramivir, the,Company,s ... and,life-threatening influenza. (Logo: http://www.newscom.com/cgi-bin/prnh/20030414/BIOCRYSTLOGO ... double-blind, placebo-controlled clinical,trial designed to test whether ...
... REINACH and BASEL, Switzerland, September 19 ,Arpida Ltd ... and clinical,data on its investigational drug iclaprim at ... Chemotherapy (ICAAC) in Chicago.,ICAAC is a major scientific ... over the world gather to discuss the latest,developments ...
Cached Biology Technology:Beckman Coulter to Present at the UBS Global Life Sciences Conference 2BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 2BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 3BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 4BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 5BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 6BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza 7Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 2Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 3Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 4
(Date:12/19/2014)... VIEW, Calif. , Dec. 18, 2014  23andMe, ... publication of a study that pinpoints fine-scale differences in ... United States . Since immigrants first ... the United States has served as a ... illuminates how American history and the ongoing mixing of ...
(Date:12/17/2014)... , Dec. 16, 2014 Valencell, a leader ... PerformTek biometric technology to industry leaders such as Intel, ... clinically validated, biometric wearable products. These products will be ... Las Vegas . ... accurate, flexible and robust – with the clinical data ...
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... Stanford scientists may be the first step toward a ... organ damage can be repaired by the body itself. ... researchers show that a human evolutionary ancestor, the sea ... suggesting that a similar regenerative process might be possible ...
... specific areas in sound processing centers in the brains ... animals watch a video. , This study confirms a ... which hearing, taste, touch, sight, and smell are each ... later integrated. The new research, led by Christoph Kayser, ...
... in the early development of new neurons in specific brain ... new research shows. How these new neurons store information ... and memory in adults. , A team of researchers ... that experience enhances the survival of new neurons in a ...
Cached Biology News:Stanford scientists make major breakthrough in regenerative medicine 2Do you hear what i see? 2Experience affects new neuron survival in adult brain; study sheds light on learning, memory 2
BD FastImmune EDTA Solution. Applications: Flow Cytometry Storage Temperature: Refrigerate(2 to 8C)...
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside C ... Cl N O 6 ,M.W.= ... ,Solution: Clear (2% in DMF) ,Biological ... and M13 ,Elemental Analysis: Agrees with ...
Antibodies were affinity purified using epitopes specific to RFC1 immobilized on solid support....
Provides continuous mixing action. For use with tubes, vials, and other containers...
Biology Products: